According to FutureWise analysis the market for huntington's disease genetic testing in 2023 is US$ 23.47 million, and is expected to reach US$ 30.48 million by 2031 at a CAGR of 3.32%.
Austedo and Xenazine are the only two symptom-alleviating therapies approved for this disorder. Depression, irritability, poor coordination, small involuntary movements, and difficulty learning new information or making decisions are some of the early signs and symptoms. Mutations in the Huntington (HTT) gene cause Huntington's disease. It provides instructions for making a protein called huntingtin called Huntington (HTT). In brain nerve cells (neurons), this protein appears to play a crucial role, even though its function is unclear. The HTT mutation causes Huntington's disease by causing a DNA fragment known as a cytosine-adenine-guanine (CAG) trinucleotide repeat. By sending blood samples to a laboratory, the test can detect the gene and confirm the diagnosis, as well as be used for presymptomatic testing of carriers and high-risk candidates. Geriatric population growth and increasing prevalence of genetic diseases fueled market growth. Moreover, with an increasing number of initiatives by public and private organizations to raise awareness about Huntington's disease, the genetic testing market is experiencing significant growth. Furthermore, researchers are increasingly focusing on developing new technologies and conducting research on genetic disorders, which are expected to drive the growth of the market. As healthcare expenditures rise, regulations improve, and funding and reimbursement policies improve, this market is expected to continue to grow. The market's growth is expected to be restricted by a lack of knowledge about Huntington's disease and its diagnosis. Key factors driving the market are the falling cost of genetic tests, the high prevalence of HD, public and private initiatives to raise awareness about HD, and the presence of a large middle-aged population. On the basis of patient gender, the male category generated the highest revenue in the global Huntington's disease genetic testing market. Many of the major markets had a slightly higher prevalence of genetic diseases in the male population. Where HD prevalence is high, this fact can be observed. Furthermore, the category is expected to grow at a faster rate during the forecast period.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Huntington's Disease Genetic testing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Huntington's Disease Genetic testing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.